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Abstract
Diffuse alveolar haemorrhage (DAH) refers to a clinical syndrome resulting from injury of the alveolar capillaries, arterioles and 
venules leading to red blood cel accumulation in the distal air spaces. The conditions associated with DAH and underlying disease 
determine the prognosis and the treatment regimen. The coexistence of DAH with venous thromboembolism (VTE) is a seroius 
problem for clinicians and poses a challenge in the therapeutic management. 
We describe a young patient who developed massive DAH in the course of anti-glomerular basement membrane (anti-GBM) 
disease (formerly called Goodpasture’s syndrome) complicated by pulmonary embolism (PE). 
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Introduction
Diffuse alveolar haemorrhage (DAH) is a po-
tentially life-threatening manifestation requiring 
aggressive treatment [1]. Most commonly, it 
occurrs in the course of systemic vasculitis. 
In turn, venous thromboembolism (VTE) is 
a frequent complication of systemic vasculitis 
that poses a challenge in the therapeutic mana-
gement when it occurs in patients with active 
haemorrhage [2]. 
We describe the young patient who develo-
ped massive DAH in the course of anti-glomerular 
basement membrane (anti-GBM) disease (former-
ly called Goodpasture’s syndrome) complicated 
by pulmonary embolism (PE). 
Case report
A 21-year-old woman who had a history of 
smoking was referred to a regional hospital because 
of severe anaemia and pulmonary infiltrates in che-
st-X ray (Fig. 1). She complained of weakness and 
fatigue, but she did not have cough, dyspnoea nor 
haemoptysis. For 2 years she used hormonal contra-
ception. Upon admission, the patient’s haemoglobin 
was 5.8 g/dl. Basing on the endoscopic examination 
of the gastrointestinal tract, bleeding was excluded. 
Serum tumour markers (Ca125, CEA-carcinoembry-
onic antigen, AFP-alpha fetoprotein, hCG-human 
chorionic gonadotropin) were absent. Bone marrow 
biopsy showed no pathology. Chest computed tomo-
graphy (CT) scans revealed centrilobular nodules 
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Figure 1. Posteroanterior chest X-ray shows bilateral ill-defined para-
hilar and lower-lobe opacities
BA C
Figure 2 A, B — CT scans at the level of lower lobes. In comparison to the previous exam from two weeks there is progression of bilateral ill-defined 
parahilar and lower-lobe opacities. Moreover, CT scans show infarction of lingula; C — axial CT pulmonary aniogiogram shows  intraluminal filling 
defect within the right lower  lobe  pulmonary artery and segmental arteries of the left lower lobe
in both lungs forming the areas of ground-glass 
attenuation (Fig. 2A). After blood transfusion, the 
concentration of haemoglobin increased to 8.5 g/dl, 
but 1 week later, haemoptysis occurred with re
-decrease in haemoglobin. The patient received 
antibiotics and underwent blood transfusion again 
and was transferred to our Department for further 
diagnosis (The National Research Institute of Tu-
berculosis and Lung Diseases in Warsaw). 
Upon admission, the woman complained of 
small haemoptysis, but she was in good general 
condition. Respiratory rate was normal, but heart 
rate accelerated to 100/min. Blood pressure was 
120/80 mm Hg. No changes of hearing over the 
lung were found. The lower limbs were normal, 
without oedema or swelling, without varicose 
vein. The number of points on the Wells scale 
(Table 1) was < 0, which indicated a low proba-
bility of DVT (deep venous thrombosis) [3]. The 
haemoglobin concentration was 11 g/dl and MCV 
(mean corpuscular volume), ferritin and TIBC 
(total iron binding capacity) were normal, but 
reticulocyte count was mildly elevated. The levels 
of liver enzymes, fibrinogen and coagulation pa-
rameters were within normal limits, but d-dimer 
and C-reactive protein were raised. Serum cre-
atinine and calculated glomerular filtration rate 
(GFR) were normal, the urine sediment was active 
(microscopic erythrocyturia). The patient had no 
respiratory failure, the oxygen tension in blood 
was 79 mm Hg, with hypocapnia and respiratory 
alkalosis. The carbon monoxide diffusing capacity 
(DLCO) was reduced to a mild level. Because the 
patient used hormonal contraception for 2 years, 
angio-CT was performed despite the low proba-
bility of DVT in the clinical evaluation. Chest CT 
scans showed extensive progression of ground 
glass attenuation areas and bilateral pulmonary 
embolism with lung infarct in lingula (Fig. 2B, C). 
Deep venous thromboembolism in duplex sono-
graphy was excluded. On bronchoscopy, diffuse 
bleeding was detectable, which together with 
Table 1. Wells scale (adapted from [3])
Clinical feature Score
Active cancer (ongoing treatment ongoing or within 
previous 6 months or palliative)
1
Paralysis, paresis, or recent plaster immobilisation  
of the lower extremities
1
Recently bedridden for more than 3 days or major 
surgery within 4 weeks
1
Localised tenderness along the distribution of the deep 
venous system
1
Entire leg swollen 1
Calf swelling by more than 3 cm when compared  
with the asymptomatic leg (measured 10 cm below 
tibial tuberosity)
1
Pitting oedema (greater in the symptomatic leg) 1
Collateral superficial veins (non-varicose) 1
Alternative diagnosis as likely or greater than that  
of deep-vein thrombosis
–2
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Figure 3 A, B. CT scans (axial reformations) show complete regression of ground-glass opacities after six months
A B
the clinical symptoms, anaemia and chest CT 
image corresponded to diffuse alveolar haemor-
rhage. Immunological laboratory tests showed 
high positive titres for anti-glomerular basement 
membrane antibodies (anti-GBM = 146 U/ml, en-
zyme-linked immunosorbent assay, ELISA) in se-
rum. Finally, anti-GBM disease with concomitant 
pulmonary embolism was diagnosed. Indications 
for the treatment of each of the diagnosed diseases 
were contradictory and mutually exclusive. For 
the best care, the patient was transferred to the 
Intensive Care Unit. Treatment was started with 
a 3-day course of intravenous methylprednisolo-
ne (500 mg/day), and then oral prednisone with 
cyclophosphamide was implemented. During the 
second pulse of steroids, anticoagulation with 
unfractionated heparin (UH) was added. The to-
lerance of treatment was good and there were no 
complications, so UH was turned into a low-mole-
cular-weight heparin (LMWH). As a result of treat-
ment, a quick clinical, immunological and radio-
logical improvement was obtained (Fig. 3A, 3B). 
The control urine analysis showed no blood, and 
renal function was still maintained (calculated 
GFR was 89 ml/min). 
Discussion
DAH refers to a clinical syndrome resulting 
from injury of the alveolar capillaries, arterioles 
and venules leading to red blood cell accumula-
tion in the distal air spaces. Usually, it is defined 
by the clinical triad of haemoptysis, anaemia 
and hypoxaemia, but the final diagnosis requires 
confirmation by bronchoscopy in which serial 
bronchoalveolar lavage samples reveal persistent 
haemorrhagic fluid [1]. The most common causes 
of DAH are antineutrophil cytoplasm antibody 
(ANCA) associated vasculitis (AAV) and anti-GBM 
disease [4]. 
The incidence of anti-GBM disease is esti-
mated to be 1 case per milion per year. The age 
distribution is bimodal, 20–30 years and 60–70 
years. The prevalence of the disease is higher in 
men in the younger age group and women in the 
older age subgroup [5, 6]. Clinical manifestation 
is usually characterised by the combination of 
glomerulonephritis and DAH accompanied by 
anti-GBM in serum and/or tissue. Serologic assay 
for IgG anti-GBM antibodies are highly sensitive 
(> 95%) and specific (> 97%) for the disease, 
but not in all patients it is positive. Szczykowska 
et al. [7] described a 59-year-old patient with clas-
sic clinical presentation of anti-GBM disease with 
supporting histologic and radiologic evidence but 
with ambiguous serological evidence [7]. 
The aetiology of anti-GBM disease is not com-
pletely understood. The recent literature shows 
that an initial insult to the pulmonary vasculature 
is required for exposure of the alveolar capillaries 
to the anti-GBM antibodies, and predisposing 
factors for such exposure include the following: 
association with HLA-DR15, exposure to organic 
solvents or hydrocarbons, smoking, infection, 
cocaine inhalation, exposure to metal dusts and 
lymphocyte-depletion therapy [6, 8–10]. Our 
patient was a young 21-year-old woman with no 
medical history. She had no evident exposure 
to environmental predisposing factors, but she 
smoked cigarettes, which could have an impact 
on the occurrence of the disease. 
VTE is a frequent complication of systemic 
vasculitis, but its presence in anti-GBM disease 
is very rare. The occurrence of VTE should be 
treated with anticoagulants, but on the other 
side — anticoagulation may increase pulmo-
nary bleeding. De Souza et al. [11] presented 
their experience of dealing with AAV patients 
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Table 3. Haemostating changes during oral contraceptive 
use (adapted from [12])
Haemostating parameter Change during oral  
contraceptive use
Procoagulant factors
fibrynogen, V, VII, VIII, IX, X, XII
XI
Von Willebrand factor
increase
no change or increase
no change
Anticoagulant proteins
antithrombin
protein C 
protein S
resistance to activated protein C (ratio)
decrease
no change or increase
decrease
decrease
Markers of thrombin formation
F1+21, TAT2 complexes, fibrinopeptide A
d-dimer
increase
increase
Fibrinolytic factors
TAFI3, PA1 and 24
t-PA5
increase
decrease
1prothrombin fragment 1+2; 2 thrombin-antithrombin complex; 3thrombin ac-
tivatable fibrinolysis inhibitor; 4plasminogen activator inhibitor type 1 and 2; 
5tissue plasminogen activator
presenting with this combination of VTE and 
concurrent DAH. The authors showed that in 
their cohort of 35 patients with DAH secondary 
to vasculitis, 20% of the subjects had concurrent 
VTE. Among patients with DAH, 57% of cases 
were diagnosed with AAV, 29% with anti-GBM 
disease and 14% with anti-synthetase syndrome. 
VTE was diagnosed by a combination of CT an-
giography in 6 patients and duplex sonography 
in 5 subjects. Six of these patients were treated 
with an anticoagulant, mostly in the form of 
LMWH with insertion of vena cava filtres in 
half of them. This approach was successful in 
5 cases, without worsening of DAH, but pro-
voked the new onset of haemorrhage in the six 
patients 2 weeks after anticoagulation treatment 
had been initiated. One patient received a vena 
cava filter but no systemic anticoagulant. Three 
of 6 anticoagulated patients also underwent 
plasmapheresis. What is important, no patient 
died and only the patient who did not receive 
anticoagulation treatment developed a  further 
PE following treatment [11]. 
Our patient applied hormonal contraception, 
which was a moderate risk factor for VTE (Table 2). 
Oral contraceptives modify the plasma levels of 
several coagulation factors (Table 3), but these 
changes are often modest and the concentrations 
of coagulation factors usually remain within the 
normal range [12]. The impact of transfusions 
cannot be excluded as a risk factor for VTE, too. 
Kumar et al. [13] presented a relationship between 
the red blood transfusion and an increased risk of 
VTE in neurological patients (with subarachnoid 
haemorrhage). A  dose-dependent association 
exists between the number of units transfused 
and thrombosis, the age of blood does not appear 
to play a role. Our patient was transfused twice, 
which could have a clinical relevance. It is inter-
esting that the number of points on the Wells scale 
was < 0, which indicated a  low probability of 
DVT, and the ultrasonography was negative. Only 
the angio-CT revealed pulmonary embolism, but 
hypocapnia was a suggesting factor for the dis-
ease. Our patient was treated with immunosup-
pression and anticoagulation first in the form of 
UH in order to better control treatment. Initially, 
she was monitored in the ICU, but no complica-
tions of the treatment were observed. The patient 
did not have DVT, and filter implantation was not 
neccesary. Due to the preserved renal function 
and good clinical and immunological response 
to immunosuppressive therapy, plasmapheresis 
has not been applied. 
The prognosis in the anti-GBM disease is se-
rious and it can lead to death. In the series of 122 
French patients, three predictive factors of death 
within the first 12 months were identified: being 
aged > 60 years, a low number of plasmapheresis 
sessions and the requirement for an alternative 
immunosuppressive agent because of refractory 
or relapsing anti-GBM disease [14]. New data 
indicate that preexisting chronic interstitial 
pneumonia is an independent factor of a poor 
prognosis in anti-GBM disease. Tashiro et al. [15] 
reported a case of anti-GBM disease complicated 
by preexisting chronic interstitial pneumonia 
Table 2. Risk factors for venous thromboembolism (adapted from [12])
Strong risk factors (odds ratio > 10) Moderate risk factors (odds ratio 2–9) Weak risk factors (odds ratio < 2)
1) trauma or fractures
2) major orthopaedic surgery
3) oncological surgery
1) non-oncological surgery
2) oral contraceptives and hormone replacement therapy
3) pregnancy and puerperium
4) hypercoagulability
5) previous venous thromboembolism
1) age
2) bed rest (> 3 days)
3) prolonged travel
4) metabolic syndrome
5) air pollution
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and positive myeloperoxidase anti-neutrophil 
cytoplasmic antibody (pANCA). They reviewed 
six similar cases described in the literatue, and 
concluded that anti-GBM disease with preexisting 
interstitial pneumonia and pANCA is related to 
a poor prognosis. In the case of our patient, there 
were no unfavourable factors, therefore the prog-
nosis was good. 
This case emphasises the need for awareness 
of the possibility of VTE in patients with active 
DAH, especially, when risk factors are involved. It 
presents a rare case of the coexistence of anti-GBM 
disease and PE. It shows that a good clinical con-
dition and the normal oxygen tension in the blood 
do not exclude the coexistence of these two severe 
diseases. In our patient, decreased PaC02 was the 
alarming sign suggesting VTE. It is possible, that 
the combination of VTE and DAH is more com-
mon than we imagine, as not all patients with 
DAH are routinely assessed with regard to PE or 
DVT. The clinical decision regarding the timing of 
anticoagulation is therefore important as clearly 
both immunosuppression and anticoagulation 
are a vital step in achieving favourable outcomes. 
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